11.63
전일 마감가:
$11.91
열려 있는:
$11.98
하루 거래량:
132.26K
Relative Volume:
0.06
시가총액:
$825.08M
수익:
-
순이익/손실:
$-297.11M
주가수익비율:
-2.2408
EPS:
-5.19
순현금흐름:
$-216.95M
1주 성능:
+14.26%
1개월 성능:
+19.83%
6개월 성능:
+106.81%
1년 성능:
-16.62%
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
명칭
Phathom Pharmaceuticals Inc
전화
(877) 742-8466
주소
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
PHAT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PHAT
Phathom Pharmaceuticals Inc
|
11.63 | 716.53M | 0 | -297.11M | -216.95M | -5.19 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
394.52 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
586.56 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
457.89 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
700.12 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
318.52 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-14 | 개시 | Cantor Fitzgerald | Overweight |
2024-05-03 | 개시 | Stifel | Buy |
2024-01-05 | 재확인 | Needham | Buy |
2023-08-09 | 개시 | H.C. Wainwright | Buy |
2023-05-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
2023-03-13 | 개시 | Craig Hallum | Buy |
2022-10-21 | 개시 | Jefferies | Buy |
2022-05-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2021-05-12 | 업그레이드 | Goldman | Sell → Neutral |
2021-02-17 | 개시 | BMO Capital Markets | Outperform |
2021-02-02 | 개시 | Guggenheim | Buy |
2020-06-26 | 다운그레이드 | Goldman | Neutral → Sell |
2019-11-20 | 개시 | Evercore ISI | Outperform |
2019-11-19 | 개시 | Goldman | Neutral |
2019-11-19 | 개시 | Jefferies | Buy |
2019-11-19 | 개시 | Needham | Buy |
모두보기
Phathom Pharmaceuticals Inc 주식(PHAT)의 최신 뉴스
RSI and MACD Indicate Shift in Phathom Pharmaceuticals Inc. SentimentJuly 2025 Outlook & Free Real-Time Volume Trigger Notifications - beatles.ru
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN
Phathom Says No Ownership Changes in Frazier Life Sciences Regulatory Filing - MarketScreener
Phathom Pharmaceuticals clarifies no reduction in Frazier ownership - Investing.com
Phathom Pharmaceuticals Clarifies That There Is No - GlobeNewswire
Administrative 13D Filing Update: Phathom Pharmaceuticals Confirms No Reduction in Major Shareholder Stakes - Stock Titan
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Soars 29% But It's A Story Of Risk Vs Reward - 富途牛牛
Published on: 2025-08-17 07:30:13 - metal.it
Insider Sales At Phathom Pharmaceuticals Landed A Good Price - simplywall.st
Quant Models Detect Momentum Reversal in Phathom Pharmaceuticals Inc.Analyst Upgrade & Smart Swing Trading Alerts - sundaytimes.kr
Can Phathom Pharmaceuticals Inc. Bounce Back From Weekly LowJuly 2025 Sentiment & Low Volatility Stock Recommendations - beatles.ru
Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Phathom Pharmaceuticals (NASDAQ:PHAT) Shareholders Are up 19% This Past Week, but Still in the Red Over the Last Five Years - 富途牛牛
Chartists Watching For Breakout in Phathom Pharmaceuticals Inc.Price Movement Prediction Analysis Review - beatles.ru
Phathom Pharmaceuticals Reports Strong Q2 Growth - TipRanks
Bullish Candlestick Pattern Forms in Phathom Pharmaceuticals Inc.Growth Focused Entry Plan Suggestions Issued - metal.it
Phathom projects $165M–$175M 2025 revenue as GI sales focus accelerates VOQUEZNA growth - MSN
Phathom Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q2 2025 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals (PHAT) Gets a Buy from H.C. Wainwright - The Globe and Mail
Craig-Hallum Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $17 - 富途牛牛
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $17 to $28 - 富途牛牛
Phathom 2025 Q2 Earnings Net Loss Narrows 17.1% - AInvest
Phathom Pharmaceuticals Inc (PHAT) Q2 2025 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Q2 2025: Unpacking Contradictions in Growth Strategies and Market Focus - AInvest
Phathom Pharmaceuticals Stock (PHAT) Opinions on Q2 2025 Earnings Report - Quiver Quantitative
Phathom Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Phathom Pharmaceuticals Q2 2025 slides: VOQUEZNA growth drives revenue beat - Investing.com Canada
Earnings call transcript: Phathom Pharmaceuticals Q2 2025 beats revenue expectations - Investing.com Australia
Earnings call transcript: Phathom Pharmaceuticals Q2 2025 beats revenue expectations By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals shares rise 11.41% intraday after reporting Q2 revenue beating estimates. - AInvest
Phathom Pharmaceuticals (PHAT) Q2 Earnings: Revenue Surpasses Es - GuruFocus
Phathom Pharmaceuticals Q2 2025 Financial Results - TradingView
Phathom Pharmaceuticals' Strategic Restructuring and Market Position: A Pathway to Long-Term Value Creation in a Capital-Constrained Biopharma Landscape - AInvest
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Phathom Pharmaceuticals Inc (PHAT) Q2 2025 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada
Published on: 2025-08-04 08:41:19 - metal.it
Does Phathom Pharmaceuticals Inc. stock perform well during market downturnsOutstanding trading profits - Jammu Links News
Is Phathom Pharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News
Is it the right time to buy Phathom Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
How does Phathom Pharmaceuticals Inc. generate profit in a changing economySkyrocketing investment returns - Jammu Links News
Should I hold or sell Phathom Pharmaceuticals Inc. stock in 2025Achieve impressive returns with smart timing - Jammu Links News
How many analysts rate Phathom Pharmaceuticals Inc. as a “Buy”Unlock exclusive stock market insights - Jammu Links News
When is Phathom Pharmaceuticals Inc. stock expected to show significant growthInvest smarter with data-backed trading alerts - Jammu Links News
What is the dividend policy of Phathom Pharmaceuticals Inc. stockBuild wealth steadily with proven strategies - Jammu Links News
What catalysts could drive Phathom Pharmaceuticals Inc. stock higher in 2025Free Stock Market Real-Time Monitoring - Jammu Links News
Several Insiders Invested In Phathom Pharmaceuticals Flagging Positive News - 富途牛牛
Published on: 2025-08-01 16:17:13 - metal.it
Elliott Wave Theory Predicts Pullback in Phathom Pharmaceuticals Inc.Low Risk Picks for Daily Trading Released - metal.it
Phathom Pharmaceuticals to Report Second Quarter 2025 - GlobeNewswire
Phathom Pharmaceuticals Inc (PHAT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Phathom Pharmaceuticals Inc 주식 (PHAT) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
Parikh Asit | Director |
Sep 10 '24 |
Option Exercise |
11.72 |
7,500 |
87,900 |
93,000 |
Parikh Asit | Director |
Mar 13 '25 |
Buy |
4.42 |
10,000 |
44,200 |
85,500 |
자본화:
|
볼륨(24시간):